| Caco-2 |
IC50 |
0.73 μM |
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging |
10.21203/rs.3.rs-23951/v1 |
| Caco-2 |
CC50 |
5 μM |
Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay |
10.21203/rs.3.rs-23951/v1 |
| Macrophage |
CC50 |
> 20000 nM |
Cytotoxicity against human monocyte derived macrophages after 24 hrs by MTT assay |
[PMID: 19029331]
|
| MRC5 |
IC50 |
> 64 μM |
Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs |
[PMID: 25199582]
|
| MRC5 |
IC50 |
1.25 μM |
Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay |
[PMID: 25199582]
|
| MT2 |
EC50 |
0.0007 μM |
Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay |
[PMID: 23937980]
|
| MT2 |
EC50 |
0.039 μM |
Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay |
[PMID: 23937980]
|
| MT2 |
EC50 |
0.039 μM |
Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay |
[PMID: 23937980]
|
| MT2 |
CC50 |
1.9 μM |
Cytotoxicity against human MT2 cells after 5 days by MTT assay |
[PMID: 24900627]
|
| MT4 |
EC50 |
> 20 μM |
Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay |
[PMID: 24805780]
|
| MT4 |
EC50 |
> 20 μM |
Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay |
[PMID: 24805780]
|
| MT4 |
EC50 |
0.001 μM |
Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay |
[PMID: 24805780]
|
| MT4 |
EC50 |
0.002 μM |
Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay |
[PMID: 24805780]
|
| MT4 |
EC50 |
0.003 μM |
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay |
[PMID: 24805780]
|
| MT4 |
EC50 |
0.003 μM |
Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay |
[PMID: 24805780]
|
| MT4 |
EC50 |
0.03 nM |
Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay |
[PMID: 21438533]
|
| MT4 |
EC50 |
0.04 μM |
Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay |
[PMID: 24805780]
|
| MT4 |
EC50 |
0.05 μM |
Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay |
[PMID: 24805780]
|